Home
    • Plans Blog Contact
    Kymera Therapeutics Inc logo

    Kymera Therapeutics Inc

    KYMR
    Last price US$117.37
    Market cap US$9.8b
    12M price change 182.41%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Syneos HealthSYNH Industry peer Pluri IncPLUR Industry peer Prenetics Global LtdPRE Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Kymera Therapeutics Inc Overview

    Industry: Biotechnology & Medical Research

    Sector: Healthcare

    Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Kymera Therapeutics Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 05, 2026

    Quarterly result summary

    Revenue was $65M (+465% YoY). Net loss was -$61.2M (from $76.6M). R&D expense was $119.5M.

    Revenue $65M +465% YoY
    Net loss -$61.2M from $76.6M
    R&D expense $119.5M reported
    G&A expense $21.1M reported

    What changed

    • Revenue +465% YoY to $65M.
    • Net loss was -$61.2M (from $76.6M).

    Guidance / outlook

    the Company expects to initiate Phase 3 trials in AD by mid-2027. • Enrollment is ongoing in the KT-621 BREADTH Phase 2b clinical trial in patients with moderate to severe eosinophilic asthma.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 05, 2026 SEC filing 8-K Aug 05, 2026 Earnings release Earnings release Apr 30, 2026 SEC filing 10-Q Apr 30, 2026 SEC filing 8-K Apr 30, 2026 SEC filing 10-K Feb 26, 2026 SEC filing 8-K Feb 26, 2026 Earnings release Earnings release Feb 26, 2026 SEC filing EX-99.1 Jan 13, 2026 SEC filing 8-K Jan 13, 2026 SEC filing 10-Q Nov 04, 2025

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 3.00/5
    Kymera Therapeutics Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Return on Equity

    Score 1.67/5
    Kymera Therapeutics Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Kymera Thera... KYMR US$9.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 1.18/5
    Kymera Therapeutics Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Kymera Thera... KYMR US$9.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology & Medical Research industry , Syneos Health , Pluri Inc , Prenetics Global Ltd are companies with high ratings.

    Leverage

    Score 2.85/5
    Kymera Therapeutics Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Kymera Thera... KYMR US$9.8b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Kymera Therapeutics Inc logo

    Kymera Therapeutics Inc

    US$117.37

    US$9.8b

    9.04%

    182.41%